** Heart disease drugmaker Cytokinetics' shares CYTK.O rise 5.7% to $40.17
** Rival Bristol Myers Squibb BMY.N stressed that it expects steady growth of heart drug Camzyos in 2025
** Says it is observing "strong global demand, high persistency and new patients coming on to therapy each week," especially after a recent update to its prescribing information
** The update allows for less frequent monitoring and simplifies treatment process for patients and doctors, J.P. Morgan analysts say
** "We also think the label update bodes well for the overall class and could expand the hypertrophic cardiomyopathy $(HCM)$ market," — brokerage
** CYTK is developing a rival heart drug, aficamten, to treat non-obstructive form of HCM, an inherited condition characterized by thickening of heart muscles
** CYTK is expected to report Q1 results on May 6
** As of last close, CYTK has fallen 14.7% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.